It’s generally “ethically unacceptable” agrees Dr Ruth Faden, the founder of the Johns Hopkins Berman Institute of Bioethics. Nevertheless, she said that the patient’s rights and interest have to be balanced with the potential benefits of the research to humanity as a whole

Quick Read

Google parent company Alphabet Inc.’s experimental health-care unit Verily plans to partner with hospitals in Ohio, one of the states hardest-hit by the U.S. opioid epidemic, on a tech-heavy approach to treating people with substance-abuse disorders

Quick Read

Hospitals are contemplating a future in which Alexa, or another voice avatar, becomes a virtual member of the medical team — monitoring doctor-patient interactions, suggesting treatment approaches, or even alerting caregivers to voice changes that could be an early warning of a health emergency

Quick Read

One of the namesakes of the federal “right-to-try” law confirmed Tuesday that he gained access to an experimental treatment thanks to the new law

Quick Read

A version of the club drug is expected to be approved for depression in March. Researchers think it could help treat suicidal thinking

Quick Read

Cheap and simple medical devices could improve performance and lower health-care costs, but first they have to overcome deeply rooted biases. With comments from our Nancy Kass

Quick Read

“We have created a place to come talk about research ethics that’s different from the IRB. It is an educational opportunity,” says Holly Taylor, PhD, MPH, PhD, core faculty at the Johns Hopkins Berman Institute of Bioethics. Taylor is lead author of a recent paper on a national research ethics consultation (REC) collaborative

Quick Read

The president of FamilyTreeDNA, one of the country’s largest at-home genetic testing companies, has apologized to its users for failing to disclose that it was sharing DNA data with federal investigators working to solve violent crimes

Quick Read